logo
Plus   Neg
Share
Email

Trial Alert: ASLAN Pharma's Phase II Gastric Cancer Study Fails

ASLAN Pharmaceuticals' (ASLN) phase II clinical study of Varlitinib as first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients has failed to meet the primary endpoint of significant reductions in tumor size after 12 weeks of treatment.

In the study, Varlitinib plus mFOLFOX6 was compared to placebo plus mFOLFOX6. Patients treated with Varlitinib plus mFOLFOX6 had an average tumor shrinkage of 22.0% after 12 weeks compared to 12.5% for patients treated with mFOLFOX6 alone. This difference did not reach statistical significance.

A pivotal study comparing Varlitinib and capecitabine to placebo and capecitabine in second-line biliary tract cancer, dubbed TreeTopp, is underway. The topline data from this study is expected in the second half of 2019.

ASLN closed Friday's trading at $3.55, down 15.48%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken. The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement.
Follow RTT
>